Physician profile
Gary E Voccio
NPI 1538224589
$2,135.88
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,031 · 2020: $104.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $399.55 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $347.38 | 2019-2020 | |
| Mylan Specialty L.P. | $243.59 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $155.04 | 2019-2020 | |
| Astrazeneca Pharmaceuticals Lp | $153.16 | 2019 | |
| Mallinckrodt Enterprises LLC | $130.77 | 2019 | |
| Grifols USA, LLC | $115.30 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $114.27 | 2019 | |
| Sunovion Pharmaceuticals INC. | $107.19 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $88.61 | 2019 | |
| United Therapeutics Corporation | $59.82 | 2019 | |
| Genzyme Corporation | $57.51 | 2019 | |
| Insmed, INC. | $49.00 | 2019 | |
| Allergan, INC. | $36.77 | 2019 | |
| Circassia INC. | $18.09 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $17.29 | 2020 | |
| Merck Sharp & Dohme LLC | $17.00 | 2019 | |
| La Jolla Pharmaceutical Company | $13.96 | 2019 | |
| Portola Pharmaceuticals, LLC | $11.58 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Voccio listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.